Human Albumin Csl Behring (Human Serum Albumin)

Human Albumin Csl Behring is indicated for clinical situations that require rapid restoration of intravascular volume or correction of low serum albumin levels.

• Treatment of hypovolemia associated with acute fluid loss, hemorrhage, or dehydration.
• Management of hypoalbuminemia in patients with chronic liver disease, nephrotic syndrome, or severe malnutrition.
• Supportive therapy for extensive thermal or chemical burns to maintain plasma oncotic pressure and reduce edema.
• Volume replacement during major cardiac, abdominal, or orthopedic surgical procedures.
• Resuscitation in severe polytrauma where rapid blood loss necessitates immediate plasma expansion.

• Human serum albumin in Human Albumin Csl Behring raises plasma oncotic pressure by increasing the concentration of albumin in the intravascular compartment. The added albumin binds water, drawing fluid from the interstitial space into the bloodstream, thereby expanding circulating volume. This effect supports hemodynamic stability and improves tissue perfusion without directly influencing coagulation pathways. The increase in oncotic pressure also helps to counteract capillary leak and maintains endothelial integrity.

Adverse reactions to Human Albumin Csl Behring are generally related to the protein nature of the preparation and the intravenous route.

Common

• Transient fever or chills during or shortly after infusion.
• Mild nausea, vomiting, or abdominal discomfort.
• Headache or dizziness occurring during the infusion.
• Localized urticaria or skin rash at the infusion site.
• Mild transient hypotension or hypertension observed during infusion.

Serious

• Anaphylactic or severe allergic reaction with respiratory distress.
• Volume overload leading to pulmonary edema or heart failure.
• Documented transmission of infectious agents (e.g., viral hepatitis) from plasma-derived product.
• Hemolysis resulting from incompatibility with patient’s blood type.
• Thromboembolic complications including deep vein thrombosis or pulmonary embolism.

When using Human Albumin Csl Behring, clinicians should evaluate patient history and monitor clinical parameters to minimize risks.

• Assess baseline intravascular volume and fluid balance before infusion.
• Avoid use in patients with documented hypersensitivity to human serum albumin.
• Use caution in individuals with congestive heart failure or reduced cardiac reserve.
• Monitor for signs of volume overload, such as pulmonary edema or rising central venous pressure.
• Observe blood pressure and renal function during and after administration.
• Maintain strict aseptic technique to prevent contamination of the infusion set.

Human Albumin Csl Behring may interact with other intravenous therapies or medications that affect fluid balance, coagulation, or immune response.

Avoid

• Co-administration with other plasma expanders or synthetic colloids that may exacerbate volume overload.
• Simultaneous infusion of incompatible blood products, which can cause hemolysis.
• Use with high-dose diuretics without careful monitoring, increasing risk of hypovolemia.

Use with caution

• Concurrent anticoagulant or antiplatelet therapy, as rapid volume expansion may alter bleeding risk.
• Vasopressor agents, because changes in intravascular volume can affect hemodynamic response.
• Nephrotoxic or renal‑impairing drugs, requiring close monitoring of renal function and fluid status.